Krishnan Ramaswamy

10PUBLICATIONS
15CO-AUTHORS
Molecular targetsPredictive and prognostic markersPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 24, 2025
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.

Stephen J Freedland, Agnes Hong, Nader El-Chaar

|Sep 13, 2024
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment.

Stephen J Freedland, Wei Gao, Angela Lax

|Apr 02, 2024
Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.

Daniel J George, Neeraj Agarwal, Krishnan Ramaswamy

|Mar 28, 2024
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.

Daniel J George, Krishnan Ramaswamy, Hongbo Yang

|Dec 14, 2022
Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.

Stephen J Freedland, Agnes Hong, Nader El-Chaar

|Jul 15, 2022
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.

Scott T Tagawa, Krishnan Ramaswamy, Ahong Huang

Pageof 2

Frequent Collaborators

5 joint publications

Stephen J Freedland

3 joint publications

Scott T Tagawa

3 joint publications

Daniel J George

2 joint publications

Jasmina Ivanova